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ABSTRACT  
 
The high rate of glucose uptake to fuel the bioenergetic and anabolic demands of proliferating 
cancer cells is well recognized, and exploited with 18F-2-fluoro-2-deoxyglucose positron 
emission tomography (18F-FDG-PET) to image tumors clinically. In contrast, enhanced 
glucose storage as glycogen (glycogenesis) in cancer is less well understood and the 
availability of a non-invasive method to image glycogen in vivo could provide important 
biologic insights. Here, we demonstrate that 18F-N-(methyl-(2-fluoroethyl)-1H-
[1,2,3]triazole-4-yl)glucosamine (18F-NFTG) annotates glycogenesis in cancer cells and 
tumors in vivo, measured by PET. Specificity of glycogen labeling was demonstrated by 
isolating 18F-NFTG-associated glycogen and with stable knockdown of glycogen synthase 1, 
which inhibited 18F-NFTG uptake, while oncogene (Rab25) activation-associated glycogen 
synthesis lead to increased uptake. We further show that the rate of glycogenesis is cell cycle-
regulated, enhanced during the non-proliferative state of cancer cells.  We demonstrate that 
glycogen levels, 18F-NFTG, but not 18F-FDG uptake, increase proportionally with cell density 
and G1/G0 arrest with potential application in the assessment of activation of oncogenic 
pathways related to glycogenesis and the detection of post treatment tumor quiescence. 
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INTRODUCTION 
 
The majority of tumors exhibit substantially increased levels of glucose uptake and utilization 
in comparison to non-neoplastic tissues.  These tumors use rapid glycolysis and lactate 
secretion even under normoxic conditions – a phenomenon first reported by Warburg in the 
1920s. (reviewed in (1)).  This transition - the Warburg effect (2) - provides a selective 
advantage for tumor growth, progression and protection from death (1, 3-5).   
 
In addition to increased glycolytic flux, tumor cells originating from epithelial tissues also 
accumulate glycogen (6-8). Initially thought to be limited to specific histotypes such as clear 
cell cancers, recent data suggest that this is a more generalized phenomenon, with potential 
prognostic and therapeutic implications (9, 10).    Glycogen is a branched glucose polymer, 
and the principal glucose store in mammalian cells. Glycogen is synthesized from the 
activated glucose donor, uridine diphosphate glucose (UDP-glucose), catalyzed by glycogen 
synthase (GS), the key regulatory enzyme in glycogenesis.  GS has two isoforms: GYS1 
(muscle) and GYS2 (liver) (11), controlled both by allosteric effectors (G-6-P, ATP and 
AMP) and by inhibitory phosphorylation of GS at multiple sites (12). 
 
Distinct from our perception of the cancer cell as a cell deficient in energy stores requiring 
glucose uptake and glycolysis to meet energy demands, emerging data suggest that oncogenic 
signaling and the quiescent state can induce glycogen storage in cancer cells (glycogenesis), 
and buffer bio-energetic stress.  In ovarian cancer, glycogen stores are particularly high in 
chemoresistant clear cell adenocarcinomas, and the oncogenic small GTPase, Rab25, has 
recently been shown to increase glycogen stores: resulting in increased resistance to nutrient 
deprivation induced bio-energetic stress, therapy-induced apoptosis, and poor prognosis (9). 
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In addition, when cancer cells enter the stationary growth phase (quiescence), like budding 
yeast (13, 14), they synthesize glycogen (or trehalose), with the switch to growth being 
associated with diminished glycogenesis (6, 7, 15). While the molecular mechanisms 
responsible for enhanced glycogenesis in mammalian cells are not well understood, it can be 
appreciated that non-invasive assessment of this metabolic switch could have important 
applications in cancer. Cytotoxic drugs used in cancer chemotherapy generally cause DNA 
damage, inhibit DNA replication and/or cell division and are therefore active predominantly 
in proliferative cycling cells.  Quiescent cells in tumors, such as dormant cells following 
chemotherapy and/or stem cells, therefore exhibit relative chemo-resistance.  
 
It is against this background that we sought to develop a novel non-invasive measure of tissue 
glycogen for clinical use. Previous methods used to detect glycogen, such as the 
incorporation of tritiated glucose (16), immuno-cytochemistry (17), or glucose quantification 
following glycogen hydrolysis (18), are invasive techniques requiring biopsies.  These 
methods also raise concerns regarding sampling a small region, and the ability to generalize 
to a heterogeneous tumor, that are well documented (19).  More recently, 2-[N-(7-nitrobenz-
2-oxa-1,3-diazol-4-yl) amino]-2-deoxy-D-glucose (2-NBDG), a fluorescent glucosamine 
derivative developed to measure cell viability and glucose transport, has been used to 
quantify glycogen storage in rat hepatocytes in culture (20).  Fluorescent imaging of glycogen 
synthesis by 2-NBDG is ideal for in vitro measurements in intact cells, but poor tissue 
penetration of the emitted green fluorescence precludes its use in vivo.  The substitution of 
fluoride in 18F-FDG for the C-2 hydroxyl moiety in glucose prevents metabolism past the 
second step of glycolysis catalyzed by glucose-6-phosphate isomerase; and 18F-FDG is not 
incorporated into glycogen.  By contrast, we present here a non-invasive method for the in 
vivo detection of glycogen storage by positron emission tomography exploiting a novel 
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glucosamine derivative, 18F-N-(methyl(2-fluoroethyl)-1H-[1,2,3]triazole-4-yl))glucosamine 
(18F-NFTG). 18F-NFTG retains the alpha-proton required for the initial flux into newly 
formed glycogen, analogous to 2-NBDG (Fig. 1A).  
 
 
METHODS 
 
Cell culture 
IGROV-1 ovarian adenocarcinoma cells were a kind donation from the Institute of Cancer 
Research (Sutton, Surrey, UK; 2006). Generation of HEY Rab25, HEY pcDNA and 
IOSE80ht pcDNA cells have been previously described (21) and were obtained from MD 
Anderson Cancer Center (Houston, TX, USA; 2010).  All cells were maintained in RPMI 
1640 medium, supplemented with 10% fetal calf serum, 2mM L-glutamine, 
100U.mL−1 penicillin and 100 μg.mL−1 streptomycin (Invitrogen) and were maintained at 
37°C in a humidified atmosphere containing 5% CO2. Regarding cell line authentication, 
cells were analyzed by short tandem repeat (STR) profiling (DNA Diagnostics Centre) using 
the Promega PowerPlex Fusion System just prior to publication. 
  
Cell treatments and cell density experiments 
The effect of HEY Rab25 cell density on 2-NBDG fluorescence and glycogen 
immunostaining was performed in 8-well Lab-Tek chamber slides (TermoFisher Scientific), 
seeded with 1.25×104 cells/cm2. Measurements were made at 1, 3 and 6 days post seeding.  
For all other density-dependent measurements, cells were seeded at 12.8×104 cells/cm2, 
6.4×104 cells/cm2, 3.2×104 cells/cm2 and 1.6×104 cells/cm2, with analysis performed 24h post 
seeding.   
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2-NBDG fluorescence microscopy and quantitation 
2-NBDG fluorescence microscopy was performed as previously described (20).  Briefly, cells 
were incubated with 500µM 2-NBDG at 37°C for 3h in complete growth medium in the dark.  
Cells were washed 3× with warm PBS, followed by fresh warm media.  Fluorescence 
measurements and images were obtained with at 400× magnification on a Zeiss Axiovert 
S100 inverted microscope (Carl Zeiss Ltd.).  For washout experiments, cells were maintained 
at 37°C and 5% CO2 within the microscope imaging chamber, with images taken every 20 
min. 
 
For fluorescence quantitation, HEY Rab25 cells were seeded in black 96-well tissue culture 
plates (ThermoFisher Scientific. Inc.), at cell densities described above.  Approximately 24h 
post seeding, fresh media containing 500µM 2-NBDG was added to cells.  Following 3h 
incubation, cells were washed 3× with ice-cold PBS and lysed in 50 µL RIPA buffer (Thermo 
Fisher Scientific Inc.).  Fluorescence was subsequently quantified on a PHERAstarplus 
fluorescence plate reader (BMG LABTECH  GmbH; λEx/Em=65/540nm) and normalized 
for protein content using a BCA 96-well plate assay (ThermoFisher Scientific) 
 
Quantification of total cellular glycogen  
Total cellular glycogen was evaluated in cells, seeded in 10cm plates for 24h.  Cells were 
subsequently evaluated using a colorimetric Glycogen Assay Kit from Biovision, according 
to the manufacturer’s instructions.  Samples were transferred to 96-well plates, with 
colorimetric measurements read in a Tecan Sunrise plate reader at 570nm.  Total cellular 
glycogen was normalized to protein levels using a BCA assay. 
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Radiotracer studies  
18F-NFTG synthesis and radiolabeling was performed according to previously described 
methodology (22). 
 
In vitro 18F-NFTG and 18F-FDG cell uptake 
Cells were plated into 6-well plates 24h prior to analysis.  For non-cell density-dependent 
measurements, cells were seeded at 2.4×105 cells/well of a 6-well plate.  1.0×106 cells/well 
were seeded for GYS1 shRNA experiments.  On the day of the experiment, fresh growth 
medium, containing approximately 0.74MBq 18F-NFTG or 18F-FDG, was added to individual 
wells (1mL).  Cell uptake was measured following incubation at 37°C in a humidified 
atmosphere of 5% CO2 for 3h. Plates were subsequently placed on ice, washed 3 times with 
ice-cold PBS and lysed in RIPA buffer (Thermo Fisher Scientific Inc.; 1mL, 10 min).  Cell 
lysates were transferred into counting tubes and decay-corrected radioactivity was determined 
on a gamma counter (Cobra II Auto-Gamma counter, Packard Biosciences Co.). Aliquots 
were snap-frozen and used for protein determination following radioactive decay by a BCA 
assay. Data were expressed as percent of total radioactivity incorporated into cells, 
normalized for total cellular protein.   
 
Direct glycogen labeling with 18F-NFTG 
For the assessment of direct labeling of pro- and macro-glycogen with 18F-NFTG, 5.9×106 
HEY Rab25 cells were seeded in triplicate into 10cm plates.  24h post seeding, ~3.7MBq 18F-
NFTG were added to wells and incubated for 3h at 37°C in a humidified atmosphere 
containing 5% CO2.  Cells were washed 3× with ice-cold PBS and scraped into 1mL of RIPA 
buffer, 10% TCA or 20% KOH, 65% ethanol for analysis of whole cell lysates, proglycogen 
and macroglycogen respectively.  Cells were lysed following 10× passages in an Ultra-Turrax 
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T-25 homogeniser (IKA Werke GmbH and Co. KG).  Aliquots were taken for protein 
analysis, with glycogen isolation performed as in Huang et al. (23).  Samples were 
transferred into counting tubes and decay-corrected radioactivity was determined on a gamma 
counter.  Total glycogen was assessed in samples by the glycogen colorimetric assay and 
glycogen-associated radioactivity was expressed as a percentage of radioactivity in whole cell 
lysates, normalized for glycogen content.   
 
RNA interference  
Lentiviral plasmid containing a short-hairpin RNA (shRNA) targeting human glycogen 
synthase 1 mRNA was cloned in pLKO1 lentiviral vector (Sigma) using the following 
sequence: 5’- 
CCGGCAAGGGCTGCAAGGTGTATTTCTCGAGAAATACACCTTGCAGCCCTTGTTT
TTG-3’ (TRCN0000045696). Recombinant lentiviruses were generated using a three-plasmid 
system in 293T cells as previously described (24). Viral titers were determined on 293T cells 
and target cells (HEY Rab25) transduced twice at a multiplicity of infection (MOI) 10. 
Transduced cells were continuously selected in 1µg/ml puromycin (Sigma). Knockdown of 
glycogen synthase 1 activity was measured by Western blotting. 
 
DNA cell cycle analysis 
DNA-based flow cytometric analysis of cell cycle progression was performed using 
propidium iodide (PI) in fixed, permeabilized cells according to standard procedures (25).  
Cells were analyzed in an FACS Canto Cytometer (BD Biosciences), with 10,000 cells 
counted per treatment.  
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Western blotting 
Rabbit antibody to Rab25, p27 Kip1, glycogen synthase, cdk-4, pRb, phospho-pRB 
(Ser807/811) and mouse anti-cyclin D1 and cdk-4  (1:1000 dilution; Cell Signaling 
Technology) were used in a standard western blotting protocol. A rabbit antibody to actin 
(Sigma-Aldrich Co.; 1:5000) was used as a loading control.  
 
Metabolism experiments 
To measure metabolic rates, 7.5×105 cells were plated into 6-cm dishes and cultured until 
90% confluent. At time 0, the cells were rinsed in PBS, fed with 2mL of the test medium, and 
cultured. End-point experiments proceeded for 6h, then the medium was collected and 
analyzed for metabolite abundance. 0.6mL tissue culture medium was processed by an 
automated chemical analyzer to determine glucose, lactate, glutamine and glutamate 
concentrations (BioProfile Basic4, NOVA Biomedical).  Differences in metabolite 
concentration between time-0 and end medium were used to calculate rates of nutrient 
utilization and metabolite excretion, normalized to the cellular protein content of the dish 
(26). 
 
In vivo tumor models 
All animal experiments were performed by licensed investigators in accordance with the 
United Kingdom Home Office Guidance on the Operation of the Animal (Scientific 
Procedures) Act 1986 and within published guidelines for the welfare and use of animals in 
cancer research (27).  Female BALB/c nude mice (aged 6–8 weeks; Charles River) were 
used. HEY Rab25 or IGROV-1 tumor cells (2×106) were injected subcutaneously on the back 
of mice and animals were used when the xenografts reached ~100mm3.  Tumor dimensions 
were measured continuously using a caliper and tumor volumes were calculated by the 
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equation: volume = (π/6)×a×b×c, where a, b, and c represent three orthogonal axes of the 
tumor. 
 
PET imaging studies 
Dynamic 18F-NFTG imaging scans were carried out on a dedicated small animal PET scanner 
(Siemens Inveon PET module, Siemens Medical Solutions USA, Inc.) following a bolus 
i.v. injection of ~3.7MBq of the radiotracer into tumor-bearing mice (28).  Dynamic scans 
were acquired in list mode format over 60 min. The acquired data were then sorted into 0.5 
mm sinogram bins and 19 time frames for image reconstruction (4×15s, 4×60s, and 
11×300s), which was done by filtered back projection. The Siemens Inveon Research 
Workplace software was used for visualization of radiotracer uptake in the tumor; 30–60 min 
cumulative images of the dynamic data were employed to define 3-dimensional (3D) regions 
of interest (ROIs).  Radiotracer blood retention was estimated as in (28). Care was taken to 
minimize ROI overlap with the myocardium. The count densities were averaged for all ROIs 
at each time point to obtain a time versus radioactivity curve (TAC). Tumor TACs were 
normalized to injected dose, ,and expressed as percentage injected dose per mL tissue.  The 
area under the TAC, calculated as the integral of %ID/mL from 0–60 min, and the 
normalized uptake of radiotracer at 60 min (%ID/mL60) were also used for comparisons.  For 
image visualization, iterative reconstruction was performed (3D-OSEM).   
 
Statistical analysis 
Data were expressed as mean ± standard deviation (SD) and statistical significance 
determined using Student's 2-tailed t test. ANOVA was used for multiple comparisons (Prism 
v5.0 software for windows, GraphPad Software, San Diego, CA, USA). Differences between 
groups were considered significant if P≤0.05.   
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RESULTS 
 
Rab25 overexpression increases punctate 2-NBDG staining and 18F-NFTG uptake  
2-NBDG fluorescence microscopy 
Addition of 2-NBDG to isogenic HEY Rab25 and HEY pcDNA cells resulted in rapid cellular 
uptake and retention.  The overexpression of Rab25, in HEY Rab25 cells was confirmed by 
western blotting (Fig. 1B). Washout of diffuse 2-NBDG-derived background fluorescence 
revealed punctate granular cytosolic fluorescence in both HEY Rab25 and HEY pcDNA cells.  
The number and intensity of punctate 2-NBDG fluorescent foci were qualitatively higher in 
Rab25-overexpressing HEY cells compared to empty vector HEY pcDNA cells, and 
fluorescence remained up to 4h post removal of 2-NBDG (Fig. 1C).  In non-tumorigenic 
immortalized human ovarian epithelial IOSE80ht cells, no punctate staining was observed in 
IOSE80ht after washout, with intracellular fluorescence lost by 2h (Fig. 1C).   
 
Radiosynthesis of 18F-NFTG 
We synthesized 18F-NFTG by a copper-catalyzed 1,3-dipolar cycloaddition reaction (22). For 
in vivo PET studies injection-ready 18F-NFTG was obtained from 18F-fluoride with a 
radiochemical yield of 15%±5% (non-decay-corrected) (22). The radiochemical purity was 
>98% from n=12 individual syntheses. 
 
Cell uptake of 18F-NFTG - influence of Rab25  
Temporal uptake of 18F-NFTG was assessed in HEY Rab25 and HEY pcDNA cells under the 
same conditions as 2-NBDG.  Significantly higher 18F-NFTG uptake was detected in HEY 
Rab25 (2.80±0.26% radioactivity/mg protein) compared to HEY pcDNA cells at 3h 
(2.18±0.11% radioactivity/mg protein; P=0.019; Fig. 1D).  A 30% higher 18F-NFTG uptake 
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was observed in HEY Rab25 in comparison to HEY pcDNA cells at 4h post radiotracer 
addition (3.17±0.25% radioactivity/mg protein and 2.45±0.17% radioactivity/mg protein 
respectively; P=0.014). In HEY Rab25 cells, total cellular glycogen was 51% higher than 
pcDNA control cells (Fig 1E), with 2.95±0.53 µg/mg protein and 1.95±0.15 µg/mg protein 
measured, respectively, consistent with differences in glycogen stores measured previously 
(9).   
 
Direct labeling of extractable glycogen with 18F-NFTG 
Direct labeling of glycogen with 18F-NFTG was shown following glycogen extraction, 3h 
after HEY Rab25 cells were exposed to 18F-NFTG.  In total, 69.2±2.3% intracellular 
radioactivity was associated with proglycogen, whereas macroglycogen-labeling was below 
the limit of detection (Fig. 1F).   
 
 
Glycogen synthase 1 regulates 2-NBDG staining and 18F-NFTG uptake  
While the metabolic fate of glucose and glucosamine has been well documented, the effect of 
their derivatization on metabolic flux is not known.  The potential metabolic pathways in 
which 18F-NFTG is substrate are illustrated in Fig. 2A, compared to the known fate of 18F-
FDG.  To explore the dependence of 2-NBDG and 18F-NFTG cell retention on glycogenesis, 
HEY Rab25 cells were transfected with GYS1 shRNA or control lentiviral vector.  Greater 
than 90% knockdown of GYS1 was achieved in the GYS1 shRNA cells in comparison to 
controls (Fig. 2B).  Three further GYS1 shRNA sequences produced equivalent target 
knockdown (Fig. S1).  GYS1 depletion resulted in a corresponding 5.4-fold reduction in total 
extractable glycogen (Fig. 2C), from 10.4±0.8 µg/mg protein in empty vector (EV) control 
cells to 1.9±0.1 µg/mg protein in GYS1 shRNA cells (P=0.00004; n=3).  To understand the 
 13 
effect of GYS1 knockdown and resulting glycogen depletion on metabolic pathway flux, 
cells were grown to confluency in high glucose-containing media (11.11mM), with media 
subsequently analyzed for glucose and glutamine consumption and the secretion of catabolic 
by-products (lactate and glutamate).  Under these nutrient-rich conditions there was no 
significant difference between EV control and GYS1 knockdown cells in either glucose or 
glutamine utilization (Fig. 2D).   
 
2-NBDG fluorescence microscopy qualitatively revealed a substantial decrease in staining in 
GYS1 knockdown cells versus EV controls (Fig. 2E), consistent with glycogen levels in the 
two cells, and despite minimal differences in glycolytic flux between the two lines.  In 
contrast, differences in 18F-FDG cellular retention were unremarkable between GYS1 shRNA 
and EV HEY Rab25 cells, in keeping with the minimal differences in initial glycolytic flux 
between the two cell lines. 18F-FDG uptake was reduced by just 9% in GYS1 shRNA cells in 
comparison to control cells, with 10.2±0.2% radioactivity/mg protein and 11.2±0.6% 
radioactivity/mg protein measured in cells, respectively (P=0.045; Fig. 2F).  Conversely, 
knockdown of GYS1 expression resulted in a corresponding 7.3-fold reduction in 18F-NFTG 
uptake when compared to EV control cells (7.69±0.68% radioactivity/mg protein and 
1.05±0.05% radioactivity/mg protein, respectively; P=0.00007; Fig. 2G), supporting the 
utility of substituted glucosamine derivatives, 2-NBDG and 18F-NFTG, to report GS-
mediated glycogenesis. 
 
18F-NFTG detects increased glycogen storage induced by G1/G0 cell cycle arrest  
2-NBDG fluorescence microscopy and anti-glycogen immunofluorescence 
High 2-NBDG punctate fluorescence with an anti-glycogen IgM (20, 29). was observed in 
HEY Rab25 cells when confluency was achieved in culture, 6 days post seeding (Fig. S2). 
 14 
Similarly anti-glycogen immunofluorescence staining of fixed cells also demonstrated 
granular cytosolic fluorescence, albeit with some non-specific background staining (Fig. S2).  
Overlay of 2-NBDG fluorescence and glycogen immunofluorescence images was not 
possible as 2-NBDG fluorescence was lost during fixation and permeabilization of cells.  We 
noted in washout experiments a reduction in punctate 2-NBDG staining 40 min prior to cell 
division in comparison to non-dividing cells; this effect also corresponded to an increase in 
diffuse background 2-NBDG fluorescence (Fig. S3).   
 
Confluency induces G1/G0 growth arrest, cellular senescence and glycogen accumulation  
The role of growth arrest on glycogen accumulation was further assessed by varying cell 
seeding density (confluency) from 1.6×104 cells/cm2 to 12.8×104 cells/cm2, 24h prior to 
analysis.  In the asynchronous cultures, increased seeding density resulted in a proportional 
increase in G1/G0 growth arrest, characterized by flow cytometric measurements of DNA 
content (Fig. 3A) and a decrease in phospho-pRb levels (Fig. 3B).  Furthermore, the 
quiescence marker, p27/Kip1, and β -galactosidase staining for senescence, were both 
increased at the highest cell seeding density of 12.8×104 cells/cm2 (Fig. 3B and S4, 
respectively), whereas total cyclin D1 levels remained unchanged (Fig. 3B).  A linear 
relationship between cell seeding density and total extractable glycogen was observed in 
HEY Rab25 cells, increasing from 2.95±0.53 µg/mg protein with the lowest seeding density 
(1.6×104 cells/cm2) to 6.29±0.75 µg/mg protein at the highest (12.8×104 cells/cm2) – a 2.1-
fold increase (P=0.0019; n=3; Fig. 3C).  A density-dependent increase in 2-NBDG 
fluorescence was also observed, rising 2.8-fold, from 229±63 RFU/µg protein to 629±188/µg 
protein for cells seeded at 1.6×104 cells/cm2 and 12.8×104 cells/cm2, respectively (Fig. 3D).  
Good correlation between 2-NBDG fluorescence and total cellular glycogen was measured 
(R2=0.9336; Fig. 3G). 
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18F-NFTG and 18F-FDG cellular uptake 
Having confirmed good correlation between confluency (quiescence)-induced glycogen 
storage and 2-NBDG fluorescence, in vitro uptake of 18F-NFTG was performed in HEY 
Rab25 cells.  An increase in cell density increased tracer uptake and retention.  Cells seeded 
at 1.6×104 cells/cm2 retained 3.51±0.18% radioactivity/mg protein, increasing to 6.63±0.25% 
radioactivity/mg protein at a density of 6.4×104 cells/cm2 – a 1.9-fold increase (P=0.0006; 
n=3).  The increase in 18F-NFTG uptake started to plateau at the highest density of 12.8×104 
cells/cm2 - 7.69±0.68% radioactivity/mg protein (Fig. 3E).  Overall, there was good 
correlation between 18F-NFTG uptake and total glycogen (R2=0.8998; Fig. 3G).  Similar 
experiments were conducted with 18F-FDG, to assess corresponding levels of glucose uptake.  
Although overall cellular uptake of 18F-FDG was higher in HEY Rab25 cells in comparison 
to 18F-NFTG (12.08±0.58% radioactivity/mg protein versus 7.69±0.68% radioactivity/mg 
protein respectively at 12.8×104 cells/cm2; Fig. 3F), there was no correlation between seeding 
density and 18F-FDG uptake (R2=0.0016; Fig. 3G). 
 
Increased 2-NBDG uptake is observed in the quiescent core of HEY Rab25 spheroids 
To confirm cell cycle-dependent changes in glycogen labeling as a prelude to in vivo studies, 
2-NBDG confocal microscopy was performed on HEY Rab25 multicellular tumor spheroids, 
grown in 3D culture.  Tumor cells in the core of spheroids are usually in G0, with cycling 
cells closer to the spheroid surface (30).  Approximately 20 µm Z-stacks of the spheroid (Fig. 
S5) revealed heterogeneous uptake, with maximum fluorescence visualized in the spheroid 
core, and a further region of high uptake at the rim of the spheroid.   
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Comparison between 18F-NFTG and 18F-FDG PET imaging in vivo 
18F-NFTG PET imaging was performed in size-matched HEY Rab25 xenograft-bearing nude 
mice and compared to 18F-FDG PET (Fig. 4).  18F-NFTG radiotracer distribution was 
characterized by rapid liver uptake, followed by clearance through the kidney and bladder.  
Clearance through the intestines was also observed (Fig. 4A). While 18F-NFTG did not 
accumulate in the brain, heart-specific radioactivity was still present at 60 min, accompanied 
by good tumor uptake and retention (Fig. 4B).  In comparison, the typical 18F-FDG 
distribution of high brain, heart, bladder and tumor radioactivity was observed (Fig. 4C & 
D).   
 
The kinetic profiles of tumor retention also varied considerably between the two tracers, as 
shown by the time versus radioactivity curves (TAC; Fig. 4E). Rapid tumor uptake of 18F-
NFTG, peaking at 5 min, preceded a slow wash-out of radioactivity over the remaining 55 
min.  This was contrasted with 18F-FDG, with a maximal tumor radioactivity achieved 15 min 
post injection, with subsequent stabilization of tumor-associated radioactivity (Fig. 4E).  
Radio-HPLC analysis of plasma 18F-NFTG radioactivity revealed good tracer stability, with 
100% of the parent compound still present 15 min post injection (n=3 mice; Fig. S6).  
Radiotracer uptake in the tumor was 2.9-fold higher with 18F-FDG than 18F-NFTG 60 min 
post injection (4.10±0.38% ID/mL and 1.40±0.29% ID/mL respectively; P=0.009).   
 
18F-NFTG pharmacokinetics in other major organs varied substantially compared to 18F-
FDG.  High heart-associated radioactivity, typical of 18F-FDG, was not present with 18F-
NFTG, with 42.5±5.9 %ID/mL measured with 18F-FDG in comparison to just 4.2±0.3 
%ID/mL with 18F-NFTG at 60 min post injection (Fig. 4F).  Liver 18F-NFTG radioactivity 
peaked at 5 min, followed by slow clearance, whereas rapid washout from the liver was 
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observed with 18F-FDG, with maximal radioactivity measured <1 min post injection (Fig. 
4G).  A similar profile of rapid extraction from blood and urinary elimination through the 
kidneys was evident with both radiotracers (Fig. S7 and Fig. 4H, respectively).  
 
A common confound of many oncological PET radiotracers, including 18F-FDG, is their 
inability to differentiate between neoplastic and inflammatory tissue, leading to reduced 
specificity (31).  Here, we assessed uptake of both 18F-FDG and 18F-NFTG in an aseptic 
inflammation (turpentine) model (Fig. S8).  Turpentine-induced inflammation, confirmed in 
histological sections stained with H&E, resulted in a 2.7-fold increase (P=0.003) in 18F-FDG 
uptake in treated verses untreated muscle – clearly visible in the 50-60 minute static PET 
image.  Conversely, no significant change in turpentine-treated muscle 18F-NFTG uptake was 
detectable by either PET or ex vivo biodistribution when compared to the untreated control 
contralateral muscle (P=0.10).  
 
18F-NFTG uptake correlates to glycogen levels in vitro and in vivo  
A panel of 8 human tumor cell lines were assessed for glycogen content (Fig. S9).  High total 
cellular glycogen (44.2±14.8 µg/mg protein) was measured in stationary-phase IGROV-1 
ovarian carcinoma cells, 4.8-fold higher than in HEY Rab25 cells (9.30±1.96 µg/mg protein; 
P=0.01; n=3; Fig. 5A) and, thus, were selected for further evaluation.  This difference in 
extractable glycogen correlated well to in vitro uptake of 18F-NFTG, which was 12.26±1.97% 
radioactivity/mg protein and 2.79±0.26% radioactivity/mg protein in IGROV-1 and HEY 
Rab25 cells, respectively (4.4-fold increase; P=0.001; n=3; Fig. 5B). Similarly, 18F-NFTG 
uptake in implanted IGROV-1 xenografts in vivo was 1.6-fold higher than in HEY Rab25 
tumors (AUC of 122.7±12.3%ID/mL.min-1 and 73.7±2.42%ID/mL.min-1 respectively; 
P=0.028), consistent with the higher glycogen levels measured in vitro.  In contrast to HEY 
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Rab25 xenografts, tumor-associated radioactivity in the higher glycogen content IGROV-1 
xenograft was stable between 15 and 60 min (Fig. 5C & D). 
 
 
DISCUSSION 
 
For over 30 years, aberrant glycogen metabolism has been known to be associated with the 
metabolic reprogramming that occurs in many cancers (7). Although initially thought to be 
confined to specific histotypes, recent data have shown that this is a general phenomenon. 
Little is known about the extent of glycogen storage, the mechanisms governing this 
phenotypic adaptation and role in resistance and poor prognosis.  In this study, we 
unequivocally demonstrate that measurements of 18F-NFTG uptake and retention can be used 
to detect de novo glycogenesis in tumor cells growing in culture or in tumor xenografts in 
vivo, and that the 18F-NFTG readout of glycogenesis could be used to assess the proliferative 
state of cancer cells.   
 
Recently, the phosphatidylinositol 3-kinase (PI3K) signaling pathway has been suggested as a 
key regulator of glycogenesis, linked to increased expression of the small GTPase, Rab25 (9).   
In Rab25 overexpressing cells, AKT activity was increased, leading to an augmentation of 
GSK3 phosphorylation and subsequent inactivation.  In these cells GSK3 was unable to 
phosphorylate and therefore inhibit GS activity, resulting in increased glycogen 
accumulation.  Furthermore, it was shown that inhibition of PI3K abrogated Rab25-mediated 
glycogen storage.  2-NBDG and 18F-NFTG were able to discriminate between small 
differences in glycogen synthesis in HEY cells induced by Rab25 transfection, and suggest 
potential utility as a measure of oncogenic signaling-induced changes in glycogen.  A 
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measure of oncogene-driven glycogen status may be of prognostic significance, given that 
Rab25 appears to confer a functional survival advantage to cancer cells; allowing cellular 
survival under acute nutrient stress conditions (9).    
 
In cell experiments, specificity of glycogen labeling with 2-NBDG was demonstrated by 
comparison with anti-glycogen immunofluorescence and through extraction of 18F-NFTG-
labeled proglycogen.  Glycogen labeling by these substituted glucosamine derivatives was 
proposed via the putative signaling pathway illustrated in Fig. 2A, controlled by the key 
regulator of glycogenesis, glycogen synthase.  To further elucidate the specificity of these 
tracers to report glycogenesis, specific knockdown of muscle glycogen synthase 1 by shRNA 
was employed.  GYS1 knockdown depleted intracellular glycogen stores, reduced 18F-NFTG 
uptake over 7-fold when compared to empty vector control cells and similarly reduced 2-
NBDG retention.  Furthermore, GYS1 silencing had no effect on glycolytic flux, ruling out 
non-specific metabolic effects of GYS1 silencing or off-target toxicities of the shRNA.  As 
expected, 18F-FDG was unable to annotate the glycogen status of these cells.  It is important 
to note that although complementary, measurements of the total intracellular glycogen pool 
(measured biochemically) and rate of glycogen synthesis (measured by 18F-NFTG) differ: the 
total glycogen pool is a sum of both glycogenesis and glycogenolysis, whereas 18F-NFTG has 
only been shown to measure GS-mediated glycogenesis.  Future studies are required to 
elucidate whether 18F-NFTG-associated glycogen is substrate for glycogen breakdown by 
glycogen phosphorylase.  
 
We examined whether modulation of glycogen storage during the non-proliferative state of 
cancer cells could be detected by 2-NBDG and 18F-NFTG. Induction of G0/G1 growth arrest 
in vitro by increased cell density resulted in an increase in glycogen storage, proportional to 
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the initial cell seeding concentration. In cells, G0/G1 arrest led to increased 2-NBDG and 
18F-
NFTG uptake, whereas 18F-FDG retention remained unchanged. The mechanism behind this 
increased glycogen storage remains to be fully determined.  We speculate that the high 18F-
FDG/glucose uptake attributed to the Warburg effect aims to provide the building blocks for 
cellular proliferation through, for example, the pentose phosphate shunt, whereas in quiescent 
tumor cells the excess glucose is instead diverted to glycogen. This could then be potentially 
mobilized when the cell re-enters cell cycle for both energy and as a carbon source for the 
synthesis of proteins, nucleotides and other building blocks; analogous to nutrient stress-
induced quiescence, and synthesis of glycogen and trehalose by budding yeast (13, 14).   
 
To provide further evidence for uptake of the substituted glucosamines in the quiescent state, 
we used a more sophisticated model of heterogeneous tumor cell growth - multicellular tumor 
spheroids (reviewed in (30)). In this model, we revealed elevated 2-NBDG uptake in the 
hypoxic spheroidal core, where cells are relatively quiescent (32) and express elevated GYS1 
(10). The high uptake of 2-NBDG in the rim of the spheroid may reflect improved nutrient, 
and therefore 2-NBDG, access in this region. While our focus has been on glycogenesis, it 
should be noted that other mechanisms could be responsible for the high glycogen levels in 
quiescent cells. For instance, it was shown recently that inhibition of glycogen phosphorylase 
activity and glycogenolysis in cancer leads to a p53-dependent induction of senescence, 
providing a mechanistic link between cellular glycogen and senescence (10).  The ability to 
non-invasively measure tumor proliferative state, be it cellular quiescence or senescence may 
be of great importance.    
 
Given the ability of 18F-NFTG-PET to measure cellular glycogen levels as a metabolic 
biomarker of oncogene activation (e.g. PI3K/AKT pathway by Rab25), and G1/G0 
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quiescence, we envisage that 18F-NFTG-PET could potentially be used to complement 18F-
FDG-PET imaging of tumor glycolysis. Dynamic imaging revealed distinct patterns of 18F-
NFTG tissue retention in comparison to 18F-FDG, characterized by high uptake in the kidneys 
and in glycogen-storing liver. As the liver is a frequent site of metastasis, this could limit the 
utility 18F-NFTG in these patients. However, some tumors are not 18F-FDG avid due to low 
metabolic rates. These are frequently slow growing tumors.  Based on the relationship 
between cell cycle and glycogen levels, 18F-NFTG could complement 18F-FDG in imaging of 
such tumors.  In oncology 18F-FDG-PET is also used as a marker of treatment response. 18F-
FDG can overestimate the efficacy of cytotoxic chemotherapy due to a stunning effect, 
resulting from a reduction in metabolism due to cellular ‘stress’, or quiescence of residual 
cells. The potential ability of 18F-NFTG to specifically image these quiescent cells may be an 
advantage.  Furthermore, 18F-NFTG provides improved specificity over 18F-FDG for tumor 
imaging under conditions of inflammation.   We envisage 18F-NFTG to have great 
applicability to image tumors of the upper thoracic, for example those of the breast, where 
background is minimal.  Utility in ovarian cancer, as depicted in this study, is also envisaged.   
 
We believe that this technique can be successfully transferred to the clinic, with potential 
application in both malignant and non-malignant diseases; in malignant disease the tracer 
may have a role in the assessment of activation of oncogenic pathways related to 
glycogenesis, their modulation by drugs in development, and the detection of post treatment 
quiescent residual tumor burden. 
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FIGURE LEGENDS 
 
Figure 1.  Effect of Rab25 oncogene overexpression on 2-NBDG and 18F-NFTG cellular 
accumulation. A, Chemical structures of 2-NBDG (i) and NFTG (ii). B, Representative 
western blot of Rab25 expression in HEY pcDNA and HEY Rab25 cell lines.  Actin was used 
as a loading control. C, Fluorescent microscopy images of intracellular 2-NBDG fluorescence 
in HEY Rab25, HEY pcDNA and IOSE80ht cells. Images were acquired at the given time 
points post 2-NBDG removal.  Scale bar = 20 µm.  Arrows point to representative 
accumulations of punctate fluorescent labeling.  All images were acquired at 400× 
magnification and are representative of three independent experiments.  D, Time course of 
18F-NFTG uptake in vitro in HEY Rab25 (closed circles) and HEY pcDNA (open circles) 
cancer cell lines.  E, Total cellular glycogen in HEY Rab25 and HEY pcDNA cells.  F, 18F-
NFTG radioactivity in glycogen. Direct 18F-NFTG labeling of pro- and macro-glycogen 
isolated from HEY Rab25 cells 3h post radiotracer addition.  Counts were normalized for 
extracted glycogen and presented as a percentage of radioactivity of non-extracted whole cell 
lysates.   Mean values ± SD are shown (n = 3; * P < 0.05).   
 
Figure 2. 18F-NFTG and 2-NBDG cellular retention is controlled by the glycogenic enzyme 
glycogen synthase 1.  The enzymes involved in NFTG and FDG metabolism are depicted as 
well as the signaling pathways that regulate them.  A, Putative metabolic fates of NFTG and 
known fate of FDG.  The readily-reversible and irreversible intracellular trapping steps are 
depicted. B, Glycogen Synthase 1 knockdown by shRNA in HEY Rab25 cells. C, Changes in 
total cellular glycogen in relation to GYS1 status.  D, Metabolic rates in GYS1 knockdown 
and control cells.  E, Intracellular 2-NBDG accumulation in Empty vector and GYS1 shRNA 
cells.  Scale bar = 20 µm.  F, Effect of GYS1 shRNA on 18F-FDG uptake.  G, Effect of GYS1 
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shRNA on 18F-NFTG uptake.  Mean values (bars, SD) are shown (n = 3; * P < 0.05; *** P < 
0.0001). Abbreviations: NFTG, F-N-(methyl(2-fluoroethyl)-1H-[1,2,3]triazole-4-
yl))glucosamine; NFTG-6-P, NFTG-6-phosphate; NFTG-1-P, NFTG-1-phosphate; UDP-
NFTG, uridine diphosphate NFTG; NFTG-glycogen, NFTG-associated glycogen; G6P, 
glucose 6-phosphatase; HK, hexokinase; PGM, phosphoglucomutase;  GS, glycogen 
synthase; FDG, 2-fluoro-2-deoxyglucose, FDG-6-P, FDG 6-phosphate; GYS1, glycogen 
synthase 1; Gluc, glucose; Gln, glutamine; Lac, lactate; Glu, glutamate.  
 
Figure 3.  Variations in intracellular glycogen storage and labeling as a measurement of cell 
density-dependent HEY Rab25 G1/G0 arrest. A, Representative cell cycle plots indicating 
DNA content are shown for cells seeded in a 6-well plate at 1.5 × 105 cells/well (i), 3 × 105 
cells/well (ii), 6 × 105 cells/well (iii) and 1.2 × 106 cells/well (iv).  B, Western blots for HEY 
Rab25, cultured at seeding densities at 1.5 × 105 cells/well (i), 3 × 105 cells/well (ii), 6 × 105 
cells/well (iii) and 1.2 × 106 cells/well (iv) were probed with antibodies against cell cycle 
control proteins, as indicated. Antibody to actin is shown as a loading control. C, Changes in 
total cellular glycogen in relation to HEY Rab25 seeding density.  D, Relation between cell 
seeding density and total 2-NBDG.    E, Normalized 18F-NFTG uptake and retention relative 
to cell seeding density.  F, Normalized 18F-FDG uptake and retention relative to cell seeding 
density.  (C–F), Mean values ± SD are shown (n = 3). G, Correlation between total cellular 
glycogen and 2-NBDG fluorescence (open circles), 18F-NFTG uptake (closed circles) or 18F-
FDG uptake (closed squares). All images were acquired at 100× magnification and are 
representative of three independent experiments. 
 
Figure 4.  Dynamic 18F-NFTG and 18F-FDG-PET image analysis in HEY Rab25 tumor-
bearing mice. A & C, Representative coronal PET-CT images (30–60 minutes summed 
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activity) for 18F-NFTG (A) and 18F-FDG (C). Slices were selected to represent key organs 
with high radiotracer retention. Abbreviations: H, heart; L, liver; K, kidney; B, bladder. B & 
D, Representative axial PET-CT images of HEY Rab25 tumors (30–60 minutes of summed 
activity) for 18F-NFTG (B) and 18F-FDG (D). The slice selected in (D) was chosen to 
minimize background heart radioactivity.  Tumor margins, indicated from CT image, are 
outlined in red.  For all images, the color scale was adjusted to the maximum pixel intensity. 
E, HEY Rab25 tumor time versus radioactivity curve (TAC) obtained from 60-minute 
dynamic PET imaging. Mean ± SD (n = 4 mice per group). F, 18F-NFTG and 18F-FDG heart 
TAC. G, 18F-NFTG and 18F-FDG liver TAC.  H, 18F-NFTG and 18F-FDG kidney TAC.  
Mean ± SD (n = 4 mice per group).  
 
Figure 5.  18F-NFTG uptake in IGROV-1 cells in vitro and tumors in vivo. A, A comparison 
of total extractable glycogen taken from HEY Rab25 and IGROV-1 cells grown in vitro.  B, 
In vitro 18F-NFTG uptake in HEY Rab25 and IGROV-1 cells. Mean ± SD for A & B (n = 3; 
** P < 0.01; *** P < 0.001).  C, IGROV-1 tumor TAC obtained from 60-minute dynamic 
18F-NFTG-PET imaging.  Tumor TAC from HEY Rab25 xenografts are included for 
comparison. Mean ± SD. (n = 4 mice per group). D, Representative axial CT, PET and PET-
CT images of IGROV-1 tumor-bearing mice (30–60 minutes of summed activity).  Tumor 
margins were identified from CT image (indicated by arrow). Abbreviations: H, heart. 
  
